As of April 2, 2026, NeuroMetrix Inc (NURO) reports a Gross Margin of 55.38%.
Gross Margin indicates the portion of sales revenue remaining after covering production costs, highlighting operational efficiency.
Historical Trend of NeuroMetrix Inc's Gross Margin
Over recent years, NeuroMetrix Inc's Gross Margin has shown significant volatility. The table below summarizes the historical values:
| Date | Gross Margin |
|---|---|
| 2024-12-31 | 55.38% |
| 2023-12-31 | 66.89% |
| 2022-12-31 | 69.61% |
| 2021-12-31 | 71.76% |
| 2020-12-31 | 71.14% |
This slight downward trend highlights how NeuroMetrix Inc manages its operational efficiency and pricing power over time.
Comparing NeuroMetrix Inc's Gross Margin to Peers
To better understand NeuroMetrix Inc's position, it's useful to compare its Gross Margin against industry peers. Below are selected comparisons:
| Company | Gross Margin |
|---|---|
| NeuroMetrix Inc (NURO) | 55.38% |
| Aethlon Medical Inc (AEMD) | 7775.20% |
| Stock Trend Capital Inc (PUMP.CN) | 100.00% |
| Edwards Lifesciences Corp (EW) | 78.01% |
| Calmare Therapeutics Inc (CTTC) | 71.29% |
| Imaging Dynamics Co Ltd (IDL.V) | 71.22% |
Compared to its competitors, NeuroMetrix Inc's Gross Margin is about average compared to peers, indicating industry-standard operational efficiency.